AzTrials
AzTrials

Overweight and ObesityNCT04217850

microRNA Testing for Identification of Personalized Weight Management

A study testing 250 kcal Dietary Energy Restriction and Aerobic Exercise in people with Overweight and Obesity and Weight Loss, run by North Dakota State University at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Certain blood markers are related to one's ability to successfully lose weight by diet and exercise. Currently, the laboratory tests used to measure these blood markers are expensive and time-consuming. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Overweight and Obesity, Weight Loss
What is being tested?
250 kcal Dietary Energy Restriction and Aerobic Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteUnited States
Study dates
13 Jan 2020to 30 Jun 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • generally healthy
  • body mass index 25-34.9
  • able to do physical activity and exercise

Who cannot join

  • currently participating in a structured diet or excise program,
  • pregnant,
  • currently use any nicotine product
  • diagnosed neuromuscular disease
  • diabetes,
  • uncontrolled high blood pressure,
Show all 14Show fewer
  • diagnosed cancer,
  • previously had a heart attack or other chronic heart related conditions that are not controlled with medicine
  • difficulty moving without assistive devices or walking one-quarter mile
  • are taking medications that influence muscle size (testosterone, growth hormone, etc.),
  • have had bariatric surgery
  • have a body mass greater than 350lbs,
  • fear blood, blood draws, or needles
  • adverse reaction to a blood draw in the past.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • North Dakota State University

    Fargo, North Dakota, 58102

Other trials in United States

About this study

Official title: Efficacy of microRNA Testing for Identification of Personalized Weight Management Strategy in Obese and Overweight Individuals.

Certain blood markers are related to one's ability to successfully lose weight by diet and exercise. Currently, the laboratory tests used to measure these blood markers are expensive and time-consuming. Recently, the Electrical and Computer Engineering Department, at NDSU, invented a device that may be able to measure these blood markers much more quickly and affordably. This study is designed participate, to compare our new device to previous methods. If the new sensor is successful, it will be used as diagnostic tool to personalize weight loss strategies.

Read the detailed description

Obesity is increasing exponentially in the United States (US), and over 160 million Americans are either overweight or obese. A combined diet and exercise program is the most cost-effective alternative for weight management, but there is a considerable inter-individual variability in losing weight via this method, which leaves many individuals frustrated and unable to adhere to programs throughout the lifespan. Therefore, the inability to identify the individuals who will likely succeed with diet and exercise for weight management is a critical roadblock to treating obesity. Recent studies have shown that significant variability in weight loss response to diet and exercise could be attributed in part to individual epigenetic makeup. One potential approach for monitoring the epigenetic response during weight-loss interventions is small non-coding circulating RNAs, called microRNAs (miRNAs or miRs), in the circulating blood. Studies have shown that miR-140 and 935 could be used as blood biomarkers to identify individuals who will succeed in managing their weight through diet and exercise. Moreover, during a short diet and exercise intervention, fluctuations of expression levels of biomarker miRNAs pre- and post-intervention have produced unique signature changes only in the individuals who continued the intervention for an extended period of time and attained a healthy body weight. Thus, if implemented early in a medical weight loss program it could allow for the patient to have a focused individualized treatment.

A major barrier that prevents the use of miRNAs in weight loss interventions is the inability of accurately quantifying miR-140 and 935 levels in blood samples. To minimize the miRNA contamination from red-blood cell lysis, miRNA analysis must be performed within 30 minutes of blood draw. Current miRNA detection and quantification technologies take hours/days to quantify miRNAs, require bulky equipment, and are expensive. In addition, current miRNA detection methods do not have sufficient sensitivity, detection span and specificity for clinical sample analysis. To address this need, PI. Nawarathna has recently developed a highly sensitive disposable miRNA sensor that can quantify miRNAs in point-of-care settings within 15 minutes with an assay cost of $50 per test. However, the effectiveness of the developed miRNA sensor to accurately quantify the variations of target miRNA levels (miR-140 and 935) pre- and post-diet and exercise intervention is unknown.

The objective of the proposed work is to investigate the efficacy of this miRNA sensor as a potential diagnostic device in weight management. If successful, the impact of proposed the research is two-fold: first, development of a point-of-care diagnostic device (miRNA sensor) for providing a personalized strategy for weight management (diet and exercise or bariatric surgery) and second, ability to immediately expand miRNA detection to measure other factors that can impact overall well-being (e.g.: mental and emotional health, stress, and fatigue) and diseases (e.g.: cancer, cardiovascular diseases, and others). The objective of the proposed research will be achieved through following this specific aim:

Aim: To investigate if the miRNA sensor is capable of identifying individuals who will consistently lose weight with energy restricted diet and exercise intervention.

The proposed research will develop a pilot study with overweight individuals as participants. Subjects will participate in the diet and exercise intervention for 12 weeks and miRNA analysis will be performed at 3 time points during the intervention (pre-mid-post). We will then investigate the effectiveness of the sensor.

The miRNA sensor technology, once fully developed, will be similar to a finger prick glucose monitor. Once commercially available, miRNA sensors can be purchased and used for diagnostic applications in clinics or self-testing at home or remote and rural area clinics and hospitals. Therefore, the outcomes will fundamentally advance how the individualized weight management method is selected. For this reason, this research has a positive translational impact on human health.

Being tested
250 kcal Dietary Energy Restriction, Aerobic Exercise
Medical subject headings
Overweight, Obesity, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 250 kcal Dietary Energy RestrictionOther

    The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).

  • Aerobic ExerciseOther

    Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.

Study groups in NCT04217850
Study groupRoleWhat they receive
500 kcal Energy DeficitExperimentalThe goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
Receives: Other: 250 kcal Dietary Energy Restriction; Other: Aerobic Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. micro RNA 140

    Venous blood concentrations (M) of micro RNA 140 will be measured using our sensor.

    Measured: Change across weeks 0, 6, 13

  2. micro RNA 935

    Venous blood concentrations (M) of micro RNA 935 will be measured using our sensor.

    Measured: Change across weeks 0, 6, 13

  3. Body Composition

    Change in body composition (% fat) derived from dual x-ray absorptiometry

    Measured: Change across weeks 0, 6, 13

  4. Lean body mass

    Change in lean body mass (kg) derived from dual x-ray absorptiometry

    Measured: Change across weeks 0, 6, 13

  5. Fat mass

    Change in fat mass (kg) derived from dual x-ray absorptiometry

    Measured: Change across weeks 0, 6, 13

  6. Body mass

    Change in body mass (kg) derived from scale

    Measured: Change across weeks 0, 6, 13

Secondary outcomes (5)
  1. High-density lipoprotein

    Change in high density lipoprotein (mg/dL) from Piccolo Xpress Blood Chemistry Analyzer

    Measured: Change across weeks 0, 6, 13

  2. Total cholesterol

    Change in total cholesterol (mg/dL) from Piccolo Xpress Blood Chemistry Analyzer

    Measured: Change across weeks 0, 6, 13

  3. Triglycerides

    Change in triglycerides (mg/dL) from Piccolo Xpress Blood Chemistry Analyzer

    Measured: Change across weeks 0, 6, 13

  4. Low-density lipoprotein (calculated)

    Change in low-density lipoprotein (mg/dL) from Piccolo Xpress Blood Chemistry Analyzer

    Measured: Change across weeks 0, 6, 13

  5. Very low-density lipoprotein (calculated)

    Change in very low-density lipoprotein (mg/dL) from Piccolo Xpress Blood Chemistry Analyzer

    Measured: Change across weeks 0, 6, 13

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2020
  2. Study start13 Jan 2020
  3. Primary completion4 May 2020
  4. Study completion30 Jun 2020

Why it stopped: COVID-19 pandemic

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04217850
Sponsor's protocol ID
EN20014
Status last verified
May 2022
First submitted
2 Jan 2020
Last updated
31 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing 250 kcal Dietary Energy Restriction and Aerobic Exercise in people with Overweight and Obesity and Weight Loss, run by North Dakota State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 31 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: COVID-19 pandemic). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

micro RNA 140 (time frame: Change across weeks 0, 6, 13). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in